Stem cell injections, platelet rich plasma and ivermectin do big business despite dubious or no evidence supporting their use in rheumatology. However, far from being a recent development, this type ...

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative ...

New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa ...

First Quarter 2025 Financial Results: G&A Expenses: For the quarter ended March 31, 2025, general and administrative (G&A) expenses were $4.6 million, compared to $5.4 million for the same period in ...

IntroductionThe global mesenchymal stem cells market is witnessing a significant transformation as advancements in ...

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on ...

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative ...

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may potentially allow people with type 2 diabetes to start producing more insulin ...

The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.

NextCell CSO Lindsay Davies Honoured with Multiple New Leadership Roles Within European Cell Therapy Community Davies' expertise critical to translating NextCell’s lead MSC product, ProTrans, through ...